BioTelemetry, Inc. (BEAT): Price and Financial Metrics


BioTelemetry, Inc. (BEAT)

Today's Latest Price: $53.94 USD

0.85 (1.60%)

Updated Nov 27 1:00pm

Add BEAT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

BEAT Stock Summary

  • With a price/earnings ratio of 102.88, Biotelemetry Inc P/E ratio is greater than that of about 92.02% of stocks in our set with positive earnings.
  • With a year-over-year growth in debt of -19.42%, Biotelemetry Inc's debt growth rate surpasses only 15.45% of about US stocks.
  • In terms of volatility of its share price, BEAT is more volatile than just 13.35% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biotelemetry Inc are GO, PIPR, SCPL, MEDP, and SF.
  • Visit BEAT's SEC page to see the company's official filings. To visit the company's web site, go to www.gobio.com.

BEAT Stock Price Chart Interactive Chart >

Price chart for BEAT

BEAT Price/Volume Stats

Current price $53.94 52-week high $55.85
Prev. close $53.09 52-week low $27.35
Day low $52.65 Volume 123,672
Day high $54.06 Avg. volume 330,919
50-day MA $45.49 Dividend yield N/A
200-day MA $43.45 Market Cap 1.85B

BioTelemetry, Inc. (BEAT) Company Bio


BioTelemetry Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. It operates in three segments: Patient Services, Product, and Research Services. The company is based in Malvern, Pennsylvania.

BEAT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$53.94$1998.39 3664%

We started the process of determining a valid price forecast for Biotelemetry Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Biotelemetry Inc ranked in the 94th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 3682.5% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Biotelemetry Inc, consider:

  • Its compound free cash flow growth rate, as measured over the past 4.69 years, is 1.64% -- higher than 94.51% of stocks in our DCF forecasting set.
  • The business' balance sheet suggests that 8% of the company's capital is sourced from debt; this is greater than only 20.29% of the free cash flow producing stocks we're observing.
  • As a business, Biotelemetry Inc experienced a tax rate of about 26% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 89.44% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%3590%
1%3627%
2%3664%
3%3701%
4%3738%
5%3775%

MNKKQ, RDY, ALPN, CORT, and FVE can be thought of as valuation peers to BEAT, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


BEAT Latest News Stream


Event/Time News Detail
Loading, please wait...

BEAT Latest Social Stream


Loading social stream, please wait...

View Full BEAT Social Stream

Latest BEAT News From Around the Web

Below are the latest news stories about Biotelemetry Inc that investors may wish to consider to help them evaluate BEAT as an investment opportunity.

Bullish Needham call lifts BioTelemetry, up 6%

Needham initiated BioTelemtry ([[BEAT]] +6.0%) with a Buy rating, price target of $52, indicating upside of 33% from current levels.Analyst David Saxon says that sales mix shift in Healthcare, the continued ramp of the company's Geneva Health Solutions remote monitoring, and the strong Research bookings should contribute to the company's...

Seeking Alpha | September 11, 2020

Outlook on the Cardiac Safety Services Global Market to 2026 - Featuring Bioclinica, BioTelemetry & Banook Group Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Cardiac Safety Services Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global cardiac safety services market is estimated to grow significantly during the forecast period. The growth of the market is attributed to the increasing number of clinical trials, growing outsourcing of R&D services and increasing R&D investment coupled with pharmaceutical R&D across the globe. The growing R&D expenditure is also dri

Business Wire | August 14, 2020

BioTelemetry Inc (BEAT) Q2 2020 Earnings Call Transcript

Ladies and gentlemen, good afternoon, and thank you for joining us for the BioTelemetry Second Quarter 2020 Earnings Conference Call. Such statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company in the future, to be materially different from the statements that the company's executives may make today. It is now my pleasure to turn the floor over to your host, Mr. Joseph Capper, President and CEO of BioTelemetry.

Yahoo | July 31, 2020

BioTelemetry (BEAT) Beats Q2 Earnings and Revenue Estimates

BioTelemetry (BEAT) delivered earnings and revenue surprises of 191.67% and 15.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2020

BioTelemetry, Inc. Reports Second Quarter 2020 Financial Results

Posts Strong Results and Ramps Up Business Development ActivityMALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended June 30, 2020. Company Highlights * Recognized quarterly total revenue of $99.1 million * Total revenue declined 11.4% year-over-year due to the impact of COVID-19 across most of our businesses * Reported quarterly GAAP net income of $2.3 million, or 2.3% of total revenue * Realized quarterly adjusted EBITDA of $25.6 million, or 25.8% of total revenue * Acquired Remote Patient Monitoring (“RPM”) assets from a subsidiary of Centene Corporation * Entered...

Yahoo | July 30, 2020

Read More 'BEAT' Stories Here

BEAT Price Returns

1-mo 34.28%
3-mo 35.22%
6-mo 14.33%
1-year 16.25%
3-year 110.70%
5-year 317.82%
YTD 16.50%
2019 -22.47%
2018 99.73%
2017 33.78%
2016 91.35%
2015 16.45%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8657 seconds.